\u201cBetter definition of biological subtypes of multiple myeloma is critical for the development of precision medicine treatment strategies.<\/p>\n
Our latest collaborative study is a great example of high impact team science focused on multiple myeloma: Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Mayo Clinic, University of Heidelberg, and University of W\u00fcrzburg.<\/p>\n
The study maps out the timeline of DNA damage for multiple myeloma. Findings from this work may lead to better ways to group patients by the state of their DNA and define new subtypes of disease to predict treatment strategies and outcomes.\u201d<\/p>\n
Quoting Charlotte Schubert\u2019s\u00a0post<\/a>:<\/p>\n \u201cDNA damage accumulates over time in cancer cells, pushing them to divide, thrive, and strive to take over the body. \u2018There is power in the timing\u2019 of DNA damage events, Marcella Kaddoura M.D., told me for this story for Sylvester Comprehensive Cancer Center.<\/p>\n Dr. Kaddoura and her colleagues leveraged a \u2018molecular time model\u2019 to show that DNA damage in multiple myeloma initiates decades before diagnosis, among other findings. Their DNA damage timeline may lead to new ways to type disease and predict patient response to treatment.<\/p>\n \u2018The goal is to optimize clinical outcomes,\u2019 said Sylvester physician-scientist C. Ola Landgren, about the study<\/a>, published in Nature Genetics.<\/p>\n \u2014\u2014\u2014\u2014\u2013<\/p>\n This is just one study I\u2019ve covered recently during the busy research summer at Sylvester. Others are:<\/p>\n A clinical trial<\/a> showing efficacy of the targeted drug olutasidenib\u00a0in high risk patients with myelodysplastic syndrome, led by Justin Watts.<\/p>\n A study<\/a> showing that the key DNA-binding protein TAF1 acts as a stem cell regulator to control blood development, led by Sylvester director Stephen Nimer.<\/p>\n A new model to study<\/a> the link between alcohol abuse and pancreatic cancer, led by Nagaraj Nagathihalli\u2024<\/p>\n Research<\/a> on a mutation linked to colorectal and endometrial cancer that may lead to a new combination therapy, led by Justin Taylor, who also landed the Stanley J. Glaser Foundation Research Award\u2024<\/p>\n A study showing how a new drug enables effective hematopoietic transplantation from partially matched donors. \u2018Not only can you now offer every patient a transplant, but you can also optimize other factors when looking for a donor,\u2019 said study author Antonio Jimenez Jimenez\u2024<\/p>\n \u2014\u2014\u2014\u2014\u2013<\/p>\n Sylvester has been keeping other writers occupied too, including:<\/p>\n
![\"Ola](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/08\/OncoDaily-52-1-800x528.jpg\" "\\"C.")
<\/p>\n